Compare Hilton Hotels Corporation Common Stock (HLT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs BIO-TECHNE Corp — how do they compare? Hilton Hotels Corporation Common Stock trades at $314 (market cap $70.00B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 6.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| HLT | TECH | |
|---|---|---|
Market Cap | $70.00B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $72.29 |
52-Week Low | $256.75 | $43.31 |
Enterprise Value | $83.01B | $11.32B |
Dividend Yield | 0.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $317.60, down 1.36% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and revenue growth from $12.04B in 2025 to projected $12.5B in 2026. Analyst consensus remains positive with 57% buy ratings and a $352.88 price target, though technical indicators show selling pressure near key resistance at $321.
HLT offers growth potential from travel recovery and pipeline expansion but faces risks from premium valuation (P/E 46.64), rising debt levels (debt-to-asset ratio increased to 73.88% in 2025), and labor disputes. The stock's near-term performance depends on Q3 earnings meeting expectations of $2.38 EPS and managing global demand volatility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
